Commercial and scientific update
New commercialisation partner in Asia Pacific
14 September 2022
ProBiotix Health plc (AQSE: PBX), a life sciences company developing clinically proven probiotic solutions to tackle chronic lifestyle diseases like high cholesterol, high blood pressure and atherosclerosis, announces the appointment of Nutraconnect Pte Ltd (“Nutraconnect”) to develop and implement go-to-market strategies for LPLDL® as an ingredient, and CholBiome® products, in the Asia Pacific (“APAC”) region.
Nutraconnect is a nutraceutical business growth acceleration service headquartered in Singapore. The company provides end-to-end solutions for global nutraceutical companies that are looking to establish a foundation for sustainable growth in the fragmented, but vibrant APAC market. Nutraconnect possesses an established network of industry contacts and a wealth of experience in successfully bringing innovative and science backed ingredients and products to markets in the region.
Stephen O’Hara, CEO of ProBiotix Health plc, commented: “Nutraconnect brings extensive industry expertise and a network of high-level contacts in the APAC region, combined with an extensive distribution and agency network. This agreement will help expedite the commercialisation of LPLDL® and CholBiome® in important countries in the region, whilst allowing ProBiotix to focus internal resources on developing new opportunities in dairy and building a presence in the North American market.”
For further information, please contact:
|ProBiotix Health plc||https://probiotixhealth-ir.com/|
|Stephen O’Hara, Chief Executive Officer||Contact via Walbrook below|
|Peterhouse Capital Ltd (AQSE Corporate Adviser and Broker)||Tel: 020 7220 0500|
|Mark Anwyl||Tel: 020 7469 0930|
|Walbrook PR Ltd||[email protected]|
|Anna Dunphy||Mob: 07876 741 001|
About ProBiotix - www.probiotixhealth-ir.com
ProBiotix Health was established by OptiBiotix Health Plc to develop probiotics to tackle cardiovascular disease and other lifestyle conditions which are affecting growing numbers of people across the world. Since its creation, ProBiotix has become a global leader in microbiome modulating probiotics for use in functional foods, supplements and biotherapeutics.
Independent clinical studies have shown that ProBiotix’s principal product, LPLDL®, which is protected by an extensive patent portfolio, can reduce key cardiovascular risk biomarkers: Total Cholesterol of up to 34.6%, LDL-Cholesterol by 28.4%, and apoB (biomarker of atheroschlerosis) by 28.6%. Since launching its CholBiome® products containing LPLDL® in May 2017, ProBiotix has signed over 41 agreements and its products are now commercialised in 60 countries.LPLDL® was designated Generally Recognized As Safe ("GRAS") by an independent Expert GRAS Panel in the United States in February 2019, which extends its applications from use as a supplement to use as a functional ingredient in a wide range of food, dairy, and beverage products in the USA.
Aquis-listed ProBiotix Health taps into demand for cardiovascular disease treatments
Stephen O'Hara | 23 February 2023
IG UK | Youtube